# **Special Issue**

# Chemically Modified Antisense Oligonucleotides: Promising Tools for the Therapy of Diseases

## Message from the Guest Editors

Antisense oligonucleotides (AONs) have been widely studied as regulators of gene expression by their direct interaction mainly with RNA or RNA regulating molecules. During the last 20 years, AONs have shown to have the potential to treat various diseases, such as cardiovascular diseases, diabetes, cancer, neurological diseases, and muscular dystrophies. Nevertheless, several drawbacks have been identified towards this way. Introduction of chemical modifications to AONs have shown to be beneficial in several cases, providing among other things, resistance to nucleases, stability, and increased target affinity. I would like to welcome you to submit articles and reviews on chemically modified AONs against diseases.

## **Guest Editors**

Prof. Dr. Leonidas A. Phylactou

Chief Executive Officer and Medical Director, The Cyprus Institute of Neurology & Genetics, P.O. Box 23462, Nicosia 1683, Cyprus

Dr. Nikolas Mastroyiannopoulos

Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology & Genetics, PO Box 23462, Nicosia 1683, Cyprus

### Deadline for manuscript submissions

closed (28 February 2017)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/7313

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

#### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

